New hope for rare overgrowth disorder: drug trial targets root cause
NCT ID NCT06997588
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 34 times
Summary
This study tests a daily oral drug called alpelisib in children and adults with PROS, a rare condition causing abnormal tissue growth. The goal is to see if the drug can shrink overgrowths and improve symptoms. Participants must be at least 2 years old and have active, worsening overgrowth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cinn Children Hosp Medical Center
RECRUITINGCincinnati, Ohio, 45206, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGSydney, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGSydney, New South Wales, 2031, Australia
-
Novartis Investigative Site
RECRUITINGNorth Adelaide, South Australia, 5066, Australia
-
Novartis Investigative Site
RECRUITINGSalzburg, 5020, Austria
-
Novartis Investigative Site
RECRUITINGVienna, A 1090, Austria
-
Novartis Investigative Site
RECRUITINGGhent, 9000, Belgium
-
Novartis Investigative Site
RECRUITINGAngers, 49933, France
-
Novartis Investigative Site
RECRUITINGBron, 69677, France
-
Novartis Investigative Site
RECRUITINGDijon, 21000, France
-
Novartis Investigative Site
RECRUITINGMontpellier, 34295, France
-
Novartis Investigative Site
RECRUITINGParis, 75015, France
-
Novartis Investigative Site
RECRUITINGToulouse, 31400, France
-
Novartis Investigative Site
RECRUITINGTours, 37044, France
-
Novartis Investigative Site
RECRUITINGFreiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany
-
Novartis Investigative Site
RECRUITINGLeipzig, Saxony, 04103, Germany
-
Novartis Investigative Site
RECRUITINGHalle, Saxony-Anhalt, 06120, Germany
-
Novartis Investigative Site
RECRUITINGBerlin, 13353, Germany
-
Novartis Investigative Site
RECRUITINGStuttgart, 70374, Germany
-
Novartis Investigative Site
RECRUITINGRoma, RM, 00168, Italy
-
Novartis Investigative Site
RECRUITINGTorino, TO, 10126, Italy
-
Novartis Investigative Site
RECRUITINGTrieste, TS, 34137, Italy
-
Novartis Investigative Site
RECRUITINGEsplugues, Barcelona, 08950, Spain
-
Novartis Investigative Site
RECRUITINGA Coruña, 15006, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28046, Spain
-
Novartis Investigative Site
RECRUITINGLausanne, 1011, Switzerland
-
Novartis Investigative Site
RECRUITINGLiverpool, L12 2AP, United Kingdom
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.